louisiana semaglutide gastric stasis law office legal team in glp-1 attorney glp-1 gastric stasis class action glp-1 gastric stasis law firm

SURMOUNT-5 actually showed lower GI-related discontinuation with tirzepatide (2.7%) than semaglutide (5.6%)

Retatrutide (2026) Semaglutide Mechanism: GLP-1 receptor agonist FDA Status: Approved for diabetes and weight management Expected Weight Loss: 1520% body weight Administration: Weekly injection Onset: Appetite changes within first few weeks Cost: Membership pricing at Better Med Spa see plans Tirzepatide Mechanism: Dual GIP + GLP-1 receptor agonist FDA Status: Approved for diabetes and weight management Expected Weight Loss: Up to 22% body weight Administration: Weekly injection Onset: Often faster appetite suppression Cost: Membership pricing at Better Med Spa see plans Retatrutide Mechanism: Triple agonist (GLP-1 + GIP + Glucagon) FDA Status: NOT approved investigational only Expected Weight Loss: Early data suggests very potent effects (up to 24% in trials) Administration: Weekly injection (investigational protocols) Onset: Under investigation Cost: Not yet available What Are Semaglutide, Tirzepatide, and Retatrutide

High-purity research peptides backed by third-party testing

Microdoses are generally very low doses compared to standard doses and are used off-label

Tesofensine is a serotonin-noradrenaline-dopamine reuptake inhibitor (SNDRI), a type of drug that influences the levels of neurotransmitters involved in mood, motivation, and appetite